|Bid||9.00 x 1100|
|Ask||13.75 x 3200|
|Day's Range||12.15 - 12.53|
|52 Week Range||11.76 - 31.97|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.45|
Incyte's (INCY) going gets good with another FDA approval - Jakafi for the treatment of chronic GVHD. However, the stock witnesses a decline despite the recent approvals.
Incyte (INCY) obtains FDA approval for the cream formulation of ruxolitinib for the treatment of mild to moderate atopic dermatitis.
The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval covers Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy, for DLBCL patients who are not eligible for autologous stem cell transplant (ASCT). The conditional approval is based on the results from the L-MIND study that showed the best objective respons